Aragen (Formerly GVK BIO) to Partner With Global Biopharma With a Renewed Brand Promise
2.6.2021 14:25:00 EEST | Business Wire | Press release
Aragen Life Sciences (Aragen), formerly known as GVK Biosciences and a leading contract research, development and manufacturing organization, officially marked its transition to a new brand identity. With a legacy of over 20 years of partnering with innovator life sciences companies around the world, Aragen is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms.
The global Pharmaceutical CDMO market, valued USD 160.12 billion in 2020, is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast (2021-2026), as per a report by Mordor Intelligence. India is seen as a prime location for the CDMO market, and Aragen has demonstrated strong organic growth on the back of deep domain expertise, strong global delivery capabilities, and partnerships with global biopharmaceutical and biotech clients.
Coinciding with its 20 year history and an incoming global investor, Goldman Sachs, Aragen unfolded the new brand. Manni Kantipudi, CEO of Aragen, said, “With an aspiration to be a partner of choice to the life sciences industry, we started humbly 20 years ago. With strategic partnerships and investments over the years, a new investor in the company, and a renewed focus on our customers and solutions, we are ready to take the next leap. Our brand promise of ‘Together Ahead’ and our purpose ‘In every molecule is the possibility for better health’ reflect what Aragen does best – work with our partners and make them successful in the race for better health.”
Elaborating on the new visual brand identity and brand promise, Ramesh Subramanian, Chief Commercial Officer, said, “Our new mark embodies our brand promise, Together Ahead. The seamless coming together of two forms and their collaborative movement, represent our partnerships that enable infinite possibilities for better health. Our symbol which we call ‘AURA’ embodies our distinctive personality — Ambitious, Understated, Resilient and Agile. Aragen’s brand colors are loaded with symbolism and meaning. From the deep blue colour that conveys the possibilities of science, strength and resilience, the transition is made to vibrant orange which symbolizes life, better health, as well as ambition and energy.”
“With this renewed energy and focus, the 3,100+ strong employee base of Aragen, spread across 7 sites in India and overseas, with a pool of over 400 PhDs, is standing ready to continue to serve our existing and new customers in this market.” said Chief Operating Officer, Sudhir Singh.
About Aragen Life Sciences
Aragen Life Sciences Pvt Ltd (Aragen) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005569/en/
Contact information
Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt. Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SAP and S3NS Accelerate Trusted Cloud Adoption in France With Thales as First Strategic Customer27.4.2026 09:00:00 EEST | Press release
Thales (Euronext Paris: HO): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426644177/en/ Strategic partnership (c)S3NS A decisive step in scaling trusted cloud in Europe The strategic partnership between SAP and S3NS, the trusted cloud provider established by Thales and Google Cloud, will strengthen trusted cloud capabilities in France and support Europe’s growing demand for cloud business transformation. SAP RISE private cloud edition will be deployed by SAP Sovereign Cloud on S3NS’ SecNumCloud-qualified Cloud Platform, known as PREMI3NS, by H2 2026 enabling organizations to run critical workloads in a trusted environment aligned with French and European regulations. Data will remain stored, processed, and encrypted in France under French jurisdiction, while benefiting from the best cloud technology and SAP’s full innovation stack, including AI-driven capabilities. “This partnership represents a major step forward for o
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 09:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2026. The deployment expands IQM's installed base across the Asia-Pacific region, where the company already has deployed systems in South Korea and Taiwan. TOYO will operate the quantum computer to support Japanese enterprises and researchers in developing quantum use cases, while integrating the system with high-performance computing (HPC) infrastructu
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom